Clinical Trial Update: First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS [Phase 3]

View source ↗

Summary

Phase 3 trial comparing first-line mFOLFOXIRI plus panitumumab versus mFOLFOX plus panitumumab in Ras and BRAF wild-type metastatic colorectal cancer; study com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• MFOLFOXIRI
• Panitumumab (panitumumab)

Snippet

Sponsor: Gruppo Oncologico del Nord-Ovest | Conditions: Metastatic Colorectal Cancer | Phase 3 | Status: COMPLETED